User login
Language
Anonymous's groups in this site
User is not a member of any group.
Your groups across all your sites
User is not a member of any group.
Recent Content
Recent Comments
- WHO convening meeting to discuss Mpox status in Africa 2日 19時間 ago
- Writing is on the wall for the US at COP29 --BBC 3日 17時間 ago
- Update: Biden announced vaccine doses and cash for Africa 1 month 3週 ago
- Florida's new COVID booster guidance called misinformation 1 month 3週 ago
Who's online
There are currently 0 users online.
You are here
Researchers have identified two FDA-approved drugs that may be effective against the Ebola virus. This could shorten the time for developing new treatments.
HEALTHLINE NEWS by Shawn Radcliffe June 3, 2015
With a fast-moving epidemic like Ebola, doctors need to make use of every tool at their disposal. This includes giving a second life to already-approved drugs....
One research team is hoping to ease the epidemic by shortening the lengthy drug development process.
Their approach? Sifting through hundreds of existing drugs and other compounds for ones that might work against the Ebola virus....
Additional screening narrowed the list down to two potential drug candidates: Bepridil, a calcium channel blocker used to treat heart disease, and sertraline, an antidepressant more commonly known as Zoloft.
Both drugs are already approved by the FDA, although not for use against the Ebola virus.
Read complete story.
http://www.healthline.com/health-news/zoloft-could-be-a-treatment-for-ebola-virus-060315#1
A screen of approved drugs and molecular probes identifies therapeutics with anti–Ebola virus activity
SCIENCE TRANSLATIONAL MEDICINE
Read study.
コメント
Ebola treatments are likely in our pharmacies—but
QUARTZ by Akshat Rathi June 4, 2015
....only drug trials will show whether these medications work to cure or prevent the disease in humans. And those trials are something that pharmaceutical companies aren’t likely to invest in, because both the drugs are off-patent.
“If the drug patent has expired, pharma companies won’t make money from it and thus won’t invest any money required for trials,” Jonathan Corcoran, a professor at Kings College London who has worked on drug repositioning, tells Quartz.
When a drug patent expires, no single company has an exclusive right over its sale. Thus, if one pharma company invests the millions required to run a human trial, other companies can then gin up their own generic version and profit from it, dividing up the market.
So as promising as this strategy seems, it likely could only work if government or philanthropical organizations invest money in the trials....
Read complete story.
http://qz.com/418692/drugs-to-treat-ebola-may-have-been-on-pharmacy-shelves-all-along/